Ionis (IONS) Stock Price Target Raised to $130 Following FDA Approval

H.C. Wainwright has increased Ionis Pharmaceuticals' (IONS) stock price target to $130 following FDA approval of a new treatment. This upgrade reflects a positive outlook for the company's future revenues and the anticipated impact on market share. An FDA approval typically drives higher investor confidence and market interest, potentially enhancing trading volumes and stock performance. The raise in target price indicates a belief in significant growth potential from this regulatory win.